{"id":"NCT01850602","sponsor":"Kissei Pharmaceutical Co., Ltd.","briefTitle":"A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-23","primaryCompletion":"2013-12","completion":"2013-12-10","firstPosted":"2013-05-09","resultsPosted":"2018-10-09","lastUpdate":"2018-10-09"},"enrollment":213,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemodialysis","Hyperphosphatemia"],"interventions":[{"type":"DRUG","name":"PA21","otherNames":[]},{"type":"DRUG","name":"Sevelamer hydrochloride","otherNames":[]}],"arms":[{"label":"PA21","type":"EXPERIMENTAL"},{"label":"Sevelamer hydrochloride","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of PA21 in hemodialysis patients with hyperphosphatemia","primaryOutcome":{"measure":"Adjusted Mean of Serum Phosphorus Concentrations at the End of Treatment","timeFrame":"12 weeks","effectByArm":[{"arm":"PA21","deltaMin":5,"sd":null},{"arm":"Sevelamer Hydrochloride","deltaMin":5.34,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.020"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["40576086"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":108},"commonTop":["Nasopharyngitis","Diarrhoea","Constipation"]}}